218 related articles for article (PubMed ID: 32926754)
41. Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis.
Yamashita S; Rizzo M; Su TC; Masuda D
Metabolites; 2023 May; 13(5):. PubMed ID: 37233667
[TBL] [Abstract][Full Text] [Related]
42. Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?
Fruchart JC; Hermans MP; Fruchart-Najib J; Kodama T
Curr Atheroscler Rep; 2021 Jan; 23(1):3. PubMed ID: 33392801
[TBL] [Abstract][Full Text] [Related]
43. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
44. Clinical Efficacy and Safety of Low-Dose Pemafibrate in Patients With Severe Renal Impairment: A Retrospective Study.
Shima H; Tashiro M; Inoue T; Okada K; Okamoto T; Wariishi S; Doi T; Minakuchi J
Cureus; 2024 Apr; 16(4):e57777. PubMed ID: 38715994
[TBL] [Abstract][Full Text] [Related]
45. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study.
Capanni M; Calella F; Biagini MR; Genise S; Raimondi L; Bedogni G; Svegliati-Baroni G; Sofi F; Milani S; Abbate R; Surrenti C; Casini A
Aliment Pharmacol Ther; 2006 Apr; 23(8):1143-51. PubMed ID: 16611275
[TBL] [Abstract][Full Text] [Related]
46. Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice.
Zhang Z; Diao P; Zhang X; Nakajima T; Kimura T; Tanaka N
Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35884970
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis.
Ida S; Kaneko R; Murata K
Cardiovasc Diabetol; 2019 Mar; 18(1):38. PubMed ID: 30898163
[TBL] [Abstract][Full Text] [Related]
48. Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia.
Yamashita S; Arai H; Yokote K; Araki E; Suganami H; Ishibashi S;
J Clin Lipidol; 2018; 12(5):1267-1279.e4. PubMed ID: 30077640
[TBL] [Abstract][Full Text] [Related]
49. Successful Treatment of Rapid Onset, Symptomatic de novo Non-alcoholic Steatohepatitis Following Liver Transplantation: A Case Report.
Cuschieri JR; John BK; Miick R; Ortiz JA; Hashemi N
J Clin Exp Hepatol; 2013 Mar; 3(1):70-4. PubMed ID: 25755474
[TBL] [Abstract][Full Text] [Related]
50. The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis.
Hennuyer N; Duplan I; Paquet C; Vanhoutte J; Woitrain E; Touche V; Colin S; Vallez E; Lestavel S; Lefebvre P; Staels B
Atherosclerosis; 2016 Jun; 249():200-8. PubMed ID: 27108950
[TBL] [Abstract][Full Text] [Related]
51. The risk factors for ultrasound-diagnosed non-alcoholic fatty liver disease among adolescents.
Fu CC; Chen MC; Li YM; Liu TT; Wang LY
Ann Acad Med Singap; 2009 Jan; 38(1):15-7. PubMed ID: 19221666
[TBL] [Abstract][Full Text] [Related]
52. The Chinese medicine Chai Hu Li Zhong Tang protects against non-alcoholic fatty liver disease by activating AMPKα.
Zhang M; Yuan Y; Wang Q; Li X; Men J; Lin M
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30291215
[TBL] [Abstract][Full Text] [Related]
53. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
He XX; Wu XL; Chen RP; Chen C; Liu XG; Wu BJ; Huang ZM
PLoS One; 2016; 11(10):e0162368. PubMed ID: 27711128
[TBL] [Abstract][Full Text] [Related]
54. A diet high in α-linolenic acid and monounsaturated fatty acids attenuates hepatic steatosis and alters hepatic phospholipid fatty acid profile in diet-induced obese rats.
Hanke D; Zahradka P; Mohankumar SK; Clark JL; Taylor CG
Prostaglandins Leukot Essent Fatty Acids; 2013; 89(6):391-401. PubMed ID: 24140006
[TBL] [Abstract][Full Text] [Related]
55. [Effects of Electroacupunctrue Combined with Dietary Control on Peroxisome Proliferator-activa- ted Receptor-α, and Liver Fatty Acid-binding Protein Levels in Non-alcoholic Fatty Liver Disease Rats].
Zhang Y; Tang CL; Tian Y; Yuan HZ; Yang H; Tang NZ; Gao RQ; Cao J
Zhen Ci Yan Jiu; 2015 Oct; 40(5):345-51. PubMed ID: 26669188
[TBL] [Abstract][Full Text] [Related]
56. A Significant Increase of Estimated Glomerular Filtration Rate After Switching From Fenofibrate to Pemafibrate in Type 2 Diabetic Patients.
Yanai H; Katsuyama H; Hakoshima M
Cardiol Res; 2021 Dec; 12(6):358-362. PubMed ID: 34970366
[TBL] [Abstract][Full Text] [Related]
57. Serum cholesterol levels and the ratio of polyunsaturated to saturated fatty acid as an indicator of lipid metabolism in rat liver.
Hirai K; Nakano T; Katayama Y; Amagase S
J Nutr Sci Vitaminol (Tokyo); 1985 Jun; 31(3):279-89. PubMed ID: 4067663
[TBL] [Abstract][Full Text] [Related]
58. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
59. A meal high in saturated fat evokes postprandial dyslipemia, hyperinsulinemia, and altered lipoprotein expression in obese children with and without nonalcoholic fatty liver disease.
Mager DR; Mazurak V; Rodriguez-Dimitrescu C; Vine D; Jetha M; Ball G; Yap J
JPEN J Parenter Enteral Nutr; 2013 Jul; 37(4):517-28. PubMed ID: 23223552
[TBL] [Abstract][Full Text] [Related]
60. Serum retinol binding protein 4 is associated with visceral fat in human with nonalcoholic fatty liver disease without known diabetes: a cross-sectional study.
Chang X; Yan H; Bian H; Xia M; Zhang L; Gao J; Gao X
Lipids Health Dis; 2015 Apr; 14():28. PubMed ID: 25890223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
